Table 1.
Comparison of clinicopathologic characteristics between the KRASwt, KRASG12C, and KRASother groups
| Characteristic | Total Cohort (n=604) | KRASwt (n=374) | KRASG12C (n=95) | KRASother (n=135) |
|---|---|---|---|---|
| Age at resection, years | 68 (62–74) | 68 (62–74) | 69 (64–75) | 67 (61–73) |
| Sex | ||||
| Male | 202 (33) | 130 (35) | 34 (36) | 38 (28) |
| Female | 402 (67) | 244 (65) | 61 (64) | 97 (72) |
| Smoking status | ||||
| Never | 138 (23) | 125 (33) | 4 (4.2) | 9 (6.7) |
| Ever | 466 (77) | 249 (67) | 91 (96) | 126 (93) |
| Pack-years (n=465) | 27 (15–45) | 10 (0–30) | 27 (16–43) | 30 (14–46) |
| FEV1 (n=592) | 94 (83–106) | 95 (84–108) | 90 (77–104) | 94 (83–105) |
| DLCO (n=586) | 84 (69–97) | 87 (72–99) | 79 (64–92) | 80 (66–95) |
| SUVmax (n=537) | 3.7 (1.9–7.2) | 3.4 (1.8–6.7) | 4.1 (2.3–8.1) | 4.0 (2.1–7.5) |
| Operative approach | ||||
| VATS | 521 (86) | 324 (87) | 79 (83) | 118 (87) |
| Open | 83 (14) | 50 (13) | 16 (17) | 17 (13) |
| Operative procedure | ||||
| Lobectomy or pneumonectomy | 390 (65) | 245 (66) | 61 (64) | 84 (62) |
| Sublobar | 214 (35) | 129 (34) | 34 (36) | 51 (38) |
| Pathologic tumor size, cm | 1.8 (1.2–2.8) | 1.8 (1.2–2.8) | 1.8 (1.3–2.7) | 2.0 (1.4–3.1) |
| LVI (n=599) | 248 (41) | 150 (41) | 49 (52) | 49 (36) |
| VPI | 109 (18) | 70 (19) | 20 (21) | 19 (14) |
| STAS (n=544) | 337 (62) | 183 (55) | 68 (75) | 86 (70) |
| Histologic subtype | ||||
| Lepidic | 88 (15) | 59 (16) | 10 (11) | 19 (14) |
| Acinar | 368 (61) | 218 (58) | 64 (67) | 86 (64) |
| Papillary | 43 (7.1) | 28 (7.5) | 4 (4.2) | 11 (8.1) |
| Micropapillary | 37 (6.1) | 25 (6.7) | 5 (5.3) | 7 (5.2) |
| Solid | 68 (11) | 44 (12) | 12 (13) | 12 (8.9) |
| pN status (n=603) | ||||
| N0 | 506 (84) | 311 (83) | 75 (79) | 120 (89) |
| N1 or N2 | 97 (16) | 62 (17) | 20 (21) | 15 (11) |
| pStage | ||||
| I | 447 (74) | 278 (74) | 66 (69) | 103 (76) |
| II | 95 (16) | 61 (16) | 16 (17) | 18 (13) |
| III | 62 (10) | 35 (9.4) | 13 (14) | 14 (10) |
| PD-L1 status | ||||
| None (<1%) | 343 (57) | 233 (62) | 45 (47) | 65 (48) |
| Low (1–49%) | 85 (14) | 47 (13) | 15 (16) | 23 (17) |
| High (≥50%) | 176 (29) | 94 (25) | 35 (37) | 47 (35) |
| Adjuvant therapy | 116 (19) | 68 (18) | 21 (22) | 27 (20) |
Data are no. (%) or median (interquartile range). DLCO, diffusing capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 1 second; LVI, lymphovascular invasion; PD-L1, programmed death-ligand 1; STAS, spread through air spaces; SUVmax; maximum standardized uptake value; VPI, visceral pleural invasion; wt, wild-type.